FRACTYL HEALTH, INC. — fact timeline

FRACTYL HEALTH, INC. shareholders approved Ratification of Independent Auditors at the 2026-06-10 meeting.

“For Against Abstain 107,931,959 189,715 4,114,532”

FRACTYL HEALTH, INC. shareholders approved Election of Class II Directors at the 2026-06-10 meeting.

“Director Nominee For Withheld Broker Non-Vote Marc Elia 65,196,683 9,029,601 38,009,922 Clive Meanwell, M.B., Ch.B., M.D. 63,701,054 10,525,230 38,009,922 Ian Sheffield 73,761,318 464,966 38,009,922”

FRACTYL HEALTH, INC. reported the quarter ended March 31, 2026 results: net income $9.2 million. Guidance reaffirmed.

“Fractyl Health, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026”

FRACTYL HEALTH, INC. updated its quarter and full year ended December 31, 2025 guidance (reaffirmed).

“On March 24, 2026, Fractyl Health, Inc. (the “Company”) announced its financial results for the quarter and full year ended December 31, 2025 and provided a corporate update.”

FRACTYL HEALTH, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“March 13, 2026, Fractyl Health, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until September 9, 2026, to regain compliance with th”

FRACTYL HEALTH, INC. announced a restructuring with charges of approximately $1.8 million affecting the Company (22 employees, or approximately 17% of the Company’s workforce).

“implemented by the second quarter of 2025. In connection with the Strategic Reprioritization, the Company estimates that it will incur cash charges of approximately $1.8 million related to severance, employee benefits, and other related personnel reduction costs. At this time, the Company is unable in good faith to make a determination of other estimated”

FRACTYL HEALTH, INC. reported first quarter 2024 results: revenue Revenue in the quarter ended March 31, 2024.

“Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today reported its first quarter 2024 financial results”

FRACTYL HEALTH, INC. reported financial results for quarter and year ended December 31, 2023.

“On April 1, 2024, Fractyl Health, Inc. announced its financial results for the quarter and year ended December 31, 2023 and provided a corporate update.”

FRACTYL HEALTH, INC.: Amended and restated certificate of incorporation effective upon IPO closing (effective 2024-02-06).

“On February 6, 2024, Fractyl Health, Inc.’s (the “Company”) amended and restated certificate of incorporation (the “Certificate of Incorporation”), filed with the Secretary of State of the State of Delaware on February 6, 2024, and its amended and restated bylaws (the “Bylaws”) became effective in connection with the closing of the initial public offering of shares of the Company’s common stock.”

FRACTYL HEALTH, INC.: Amended and restated bylaws effective upon IPO closing (effective 2024-02-06).

“On February 6, 2024, Fractyl Health, Inc.’s (the “Company”) amended and restated certificate of incorporation (the “Certificate of Incorporation”), filed with the Secretary of State of the State of Delaware on February 6, 2024, and its amended and restated bylaws (the “Bylaws”) became effective in connection with the closing of the initial public offering of shares of the Company’s common stock.”